Data from: Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics

Traditional means for scoring the effects of anti-cancer drugs on the growth and survival of cell lines is based on relative cell number in drug-treated and control samples and is seriously confounded by unequal division rates arising from natural biological variation and differences in culture conditions. This problem can be overcome by computing drug sensitivity on a per-division basis. The normalized growth rate inhibition (GR) approach yields per-division metrics for drug potency (GR50) and efficacy (GRmax) that are analogous to the more familiar IC50 and Emax values. In this work, we report GR-based, proliferation-corrected, drug sensitivity metrics for ~4700 pairs of breast cancer cell lines and perturbagens. Such data are broadly useful in understanding the molecular basis of therapeutic response and resistance. Here, we use them to investigate the relationship between different measures of drug sensitivity and conclude that drug potency and efficacy exhibit high variation that is only weakly correlated. To facilitate further use of these data, computed GR curves and metrics can be browsed interactively at http://www.GRbrowser.org/.传统用于定量评估抗癌药物对细胞系生长与存活影响的方法，以药物处理组与对照组样本中的相对细胞数为计算基础，但会因天然生物学变异与培养条件差异导致的细胞分裂速率不均，受到严重的混杂偏倚干扰。通过以每细胞分裂为单位计算药物敏感性，可有效解决该问题。标准化生长速率抑制（Normalized Growth Rate Inhibition, GR）方法可生成基于每细胞分裂的药物效力指标GR50与药物效能指标GRmax，二者与广为熟知的IC50及Emax值具有相似的对应关系。本研究报道了基于GR、经增殖校正的药物敏感性指标，涵盖约4700对乳腺癌细胞系与扰动因子（perturbagens）组合。此类数据对于阐明治疗应答与耐药性的分子机制具有广泛的应用价值。本研究利用该类指标探究了不同药物敏感性测量方式之间的关联，并得出结论：药物效力与药物效能存在显著差异，且二者仅呈弱相关关系。为便于后续对该类数据的复用，可通过http://www.GRbrowser.org/交互式浏览计算得到的GR曲线与相关指标。